GSK’s FluLaval Approval Raises Estimated Influenza Vaccine Doses To 115 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
FluLaval is approved by FDA for immunization of adults against influenza Oct. 5.
You may also be interested in...
GSK Vaccine Manufacturing Plan Alternates Pandemic And Seasonal Flu
Results from one of two Phase I pandemic flu vaccine trials in the third quarter will support accelerated European regulatory efforts.
GSK’s Second Flu Vaccine Would Boost Capacity To 30 Mil. Doses
GSK submits a BLA for FluLaval, acquired as part of its 2005 purchase of ID Biomedical, to FDA March 23.
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.